Symbiotec Pharmalab IPO: Rs 1,757 Cr Issue Opens Aug 24
Symbiotec Pharmalab IPO launch represented by pharmaceutical and financial symbols.
Key Highlights
Symbiotec Pharmalab’s Rs 1,757 crore IPO launches August 24, 2026, with a price band of Rs 938-988. Subscription closes August 27.
Symbiotec Pharmalab Limited is set to launch its (IPO) on August 24, 2026, aiming to raise Rs. 1,757 crore. The subscription window will close on August 27, 2026, with shares expected to list on the and by September 1, 2026.
The IPO includes a fresh issue of 0.15 crore equity shares, totaling Rs. 150 crore, alongside an (OFS) of 1.63 crore shares worth Rs. 1,607 crore. Shares are priced between Rs. 938 and Rs. 988.
Key IPO Figures
- Total IPO Size: Rs. 1,757 crore
- Value: Rs. 150 crore
- Offer for Sale Value: Rs. 1,607 crore
- : Rs. 938 to Rs. 988 per share
- (GMP) as of August 21, 2026: 32.39%
- GMP Share Price: Rs. 1,308 (a premium of Rs. 320 over the cap price)
Symbiotec Pharmalab, incorporated in 2002, specializes in developing and manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company boasts over 30 years of industry experience, serving both domestic and international markets.
OFS Participants & Utilisation
The Offer for Sale involves significant contributions from multiple entities. Symbiotec Pharmalab will not receive any proceeds from this component of the IPO.
- Satwani Holdings LLP: Rs. 144 crore
- Rosewood Investments: Rs. 988 crore
- India Business Excellence Fund–III: Rs. 475 crore
Proceeds from the fresh issue are designated for specific purposes. Up to Rs. 112.50 crore will go towards repaying or prepaying outstanding borrowings, with the remainder allocated for general corporate needs. This debt reduction is anticipated to lower finance costs and enhance financial flexibility for the company.
Financial Performance Highlights
The company has shown consistent financial growth leading up to the IPO. Its revenue and profitability metrics indicate a strengthening position.
- from operations (FY24 to FY26): Increased from Rs. 716.25 crore to Rs. 869.15 crore
- (PAT) in FY26: Rs. 109.90 crore (13.55% growth after FY25)
- in FY26: Rs. 231.97 crore (26.59% margin)
- in FY26: 12.60%
- Debt-to-Equity Ratio (FY25 to FY26): Improved from 0.64x to 0.33x
- in FY26: Rs. 1,158.64 crore
Symbiotec Pharmalab operates two industrial-scale API manufacturing facilities as of June 30, 2025. The company holds key regulatory approvals, including from the US FDA, EU-GMP, and the Ministry of Food and Drug Safety, Korea.